Document:

EX-10.33

 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

EXHIBIT 10.33

AMENDMENT 

This Amendment made and executed as of this 23rd day of May, 2006 (hereinafter referred
to as the “Amendment”) constitutes a valid and enforceable amendment to the Amended and Restated
License and Supply Agreement of the 1st day of January, 2005 (hereinafter referred to as
the “Agreement”), between Orion Corporation, a corporation existing under the laws of Finland and
having its principal office at Orionintie 1, 02200 Espoo, Finland (hereinafter referred to as
“Orion”) and GTx Inc., a corporation existing under the laws of the State of Delaware, U.S.A. and
having its principal office at 3 North Dunlap Avenue, Van Vleet Building, Memphis, Tennessee 38163,
USA (hereinafter referred to as “GTX”) (Orion and GTX collectively referred to herein as
“Parties”).

	 	 	 
	WHEREAS,

	 	the Parties have entered into the Agreement on January 1, 2005;
	 
	 	 
	WHEREAS,

	 	the Parties wish to amend the Agreement on the terms and
conditions contained herein in order to include a tablet
containing [ * ] Toremifene into the scope of Agreement as a
Orion Product;
	 
	 	 
	WHEREAS,

	 	the Parties are continuing to discuss in good faith Orion’s
supply price of the [ * ] tablets which are to be marketed,
distributed and sold outside of the United States and contemplate
that another amendment to the Agreement would be needed to
evidence any subsequent agreement of the Parties pertaining
thereto; and
	 
	 	 
	WHEREAS,

	 	the Parties wish that all other terms and conditions of the
Agreement shall remain unchanged and shall be retained in full
force and effect unless specifically agreed otherwise herein;

NOW, THEREFORE, intending to be legally bound, and in consideration of the mutual covenants
contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto
agree as follows:

1. Unless indicated otherwise in this Amendment, the terms in this Amendment with
initial letters capitalized, whether used in the singular or plural, shall have the
meaning set forth in the Agreement.

2. Parties understand and agree that a tablet containing [ * ] Toremifene shall be
included into the scope of the term “Orion Product” in clause 1.34. Any and all terms
and conditions of the Agreement having reference to Orion Product shall apply to the
tablet containing [ * ] Toremifene respectively.

3. Special conditions for the tablet containing [ * ] Toremifene:

a) Price

Orion’s price of bulk Orion Product to GTX, its Affiliates or its Unaffiliated
Sublicensees for commercial purpose, delivered [ * ] (with the foregoing being
interpreted to effect [ * ]), shall be:

     [ * ] per [ * ]

b) Price Adjustment for Commercial Supply

 

			
	[
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.	 	 

1 (2)

 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

It is agreed upon by the Parties that the price of the [ * ] tablet of Orion Product
to GTX, its Affiliates or Unaffiliated Sublicensees shall be reduced [ * ] based upon
attaining certain milestone purchases of the Product as follows: if GTX purchases
annually an aggregate amount of the [ * ] tablet [ * ], the price of the tablet shall
be [ * ] per [ * ]tablet, with such price adjustment being settled between the
Parties in accordance with Section 14.8 of the Agreement.

c) The price for all [ * ] tablets for use in Clinical Trials and the price for all
Samples shall be [ * ] per [ * ] tablet.

d) Price Adjustment for the European Union (“EU”), Switzerland, Norway and the
Commonwealth of Independent States (“CIS”) (collectively, the “European Territory”)

Notwithstanding the provisions of subparagraphs 3(a) and (b) above, it is agreed by
the Parties that the Price of the [ * ] tablet of Orion Product to GTX, its
Affiliates or Unaffiliated Sublicensees shall be reduced to [ * ] for all [ * ]
Product acquired from Orion as commercial supply for sale within the European
Territory, except for Product acquired for commercial sale in [ * ] where the price
will be [ * ].

e) Responsibilities for development work, development work schedule and
specifications for the tablet containing [ * ] Toremifene are defined in Appendix 1.

f) Orion shall cover all costs of the development work of the tablet containing [ * ]
Toremifene and defined in the development plan (Appendix 1), unless otherwise agreed
in such development plan. For the avoidance of a doubt, the Parties understand and
agree that any activities or costs beyond the development plan (Appendix 1) shall be
subject to a separate written agreement between the Parties.

4. This Amendment shall become effective on May 23, 2006.

5. Except as specifically set forth and/or amended herein, all the terms and
conditions of the Agreement shall remain unchanged.

IN WITNESS WHEREOF,

the Parties, through their authorized representatives, have executed two (2)
identical copies of this Amendment.

	 	 	 	 	 	 	 	 	 	 	 
	 	 	Orion Corporation

ORION PHARMA	 	GTx Inc.
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	By: /s/ Timo Lappalainen
	 	 	 	By: /s/ Henry P. Doggrell
	 

	 	 

	 	 	 	 

	 

	 	Name: Timo Lappalainen
	 	 	 	Name: Henry P. Doggrell
	 

	 	Title: Senior Vice President
	 	 	 	Title: VP, General Counsel
	 

	 	         Orion Corporation, Orion Pharma	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	By: /s/ Matti Vaheri
	 	 	 	By:
	 

	 	 

	 	 	 	 

	 

	 	Name: Matti Vaheri
	 	 	 	Name: 
	 

	 	 	 	 	 	 	 	 

	 

	 	Title: Director
	 	 	 	Title:
	 

	 	 	 	 	 	 	 	 

	 

	 	         Orion Corporation, Orion Pharma	 	 	 	 	 	 

 

			
	[
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.	 	 

2 (2)

 

FOR DISCUSSION PURPOSES ONLY

AND

SUBJECT TO SEPARATE AGREEMENT

Appendix 1 

[ * ]

 

			
	[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.EX-10.34

 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

EXHIBIT 10.34

AMENDMENT

This Amendment made and executed as of this 30th day of June, 2006 (hereinafter referred
to as the “Amendment”) constitutes a valid and enforceable amendment to the Amended and Restated
License and Supply Agreement of the
1st day of January, 2005, as amended (hereinafter
referred to as the “Agreement”), between Orion Corporation, a corporation existing under the laws
of Finland and having its principal office at Orionintie 1, 02200 Espoo, Finland (hereinafter
referred to as “Orion”) and GTx Inc., a corporation existing under the laws of the State of
Delaware, U.S.A. and having its principal office at 3 North Dunlap Avenue, Van Veet Building, Third
Floor, Memphis, Tennessee 38163, USA (hereinafter referred to as “GTX”) (Orion and GTX collectively
referred to herein as “Parties”).

	 	 	 
	WHEREAS,

	 	the Parties have entered into the Agreement on January 1, 2005, as amended;
	 
	 	 
	WHEREAS,

	 	the Parties wish to amend the Agreement on the terms and conditions contained herein in order to agree on prices for
European Territory (defined below) regarding the tablet containing [ * ] Toremifene; and to amend the Agreement on the
terms and conditions with regard to marketing plans and reports of Orion Products sold in European Territory; and
	 
	 	 
	WHEREAS,

	 	the Parties wish that all other terms and conditions of the Agreement shall remain unchanged and shall be retained in
full force and effect unless specifically agreed otherwise herein;

NOW, THEREFORE, in tending to be legally bound, and in consideration of the mutual covenants
contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto
agree as follows:

	 	1.	 	Unless indicated otherwise in this Amendment, the terms in this
Amendment with initial letters capitalized, whether used in the singular or
plural, shall have the meaning set forth in the Agreement.
	 
	 	2.	 	Prices for the tablet containing [ * ] Toremifene in European
Territory

“European Territory” shall mean collectively the European Union (“EU”), Switzerland,
Norway, Iceland and Lichtenstein and the Commonwealth of Independent States (“CIS”).
For the avoidance of doubt, the definition of “European Territory” in the Amendment
between the Parties dated as of May 23, 2006 to the Agreement shall also be amended
for tablets containing [ * ] Toremifene to be the same definition as above.

a) Price

Orion’s price of bulk Orion Product to GTX, its Affiliates or its Unaffiliated
Sublicensees for commercial purpose and to be sold, imported, marketed and
distributed solely in European Territory, delivered [ * ] (with the foregoing being
interpreted to effect the [ * ]), shall be:

[ * ] per [ * ] tablet for commercial sale in [ * ]; and

[ * ] per [ * ] tablet for commercial sale in all other European Territory countries

Nevertheless, the weighted average price per [ * ] tablets sold in European
Territory in any calendar year shall not be less than [ * ] per [ * ] tablet. For
purposes hereof, “weighted average price” shall be calculated as follows: [ * ] per
tablet x [all tablets sold in [ * ] which GTX, its

 

			
	[ * ]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.	 	 

1.

 

Affiliates and Unaffiliated
Sublicensees believes in good faith, based upon a reasonable forecast, to be
required for the consumption in [ * ] in the calendar year] + [ * ] per tablet x
[all tablets sold in all other European Territory countries during the calendar
year], the sum of which shall be divided by the total number of tablets sold in the
European Territory during the calendar year.

In the event the “weighted average price” of all [ * ] tablets sold in the European
Territory shall be less than [ * ] per tablet for any calendar year, GTX, its
Affiliates or its Unaffiliated Sublicensees shall be required to make an additional
payment for Product supply to Orion within 90 days of the end of the calendar year
in an amount sufficient to allow the weighted average price of all [ * ] tablets
sold during the calendar year to equal [ * ] per tablet.

For the avoidance of a doubt, the Parties understand and agree that Orion is bound
to the aforementioned prices only to the extent that specifications, analyses and
stability requirements are the same than for the tablets manufactured for the USA
markets.

b) Sample Prices

Orion’s price of bulk Orion Product to GTX, its Affiliates or its Unaffiliated
Sublicensees for samples, including clinical trial samples, used solely in European
Territory, delivered [ * ] (with the foregoing being interpreted to effect [ * ]),
shall be:

[ * ] per [ * ] tablet for European Territory

For the avoidance of a doubt, the Parties understand and agree that Orion is bound
to the aforementioned prices only to the extent that specifications, analyses and
stability requirements are the same than for the tablets manufactured for the USA
markets.

	 	3.	 	Marketing Plan and Reports. Without prejudice to
Section 6.6 of the Agreement, the Parties agree on the terms with respect to
European Territory countries as follows:

Marketing Plans. GTX shall develop and provide to Orion by October 31 of
each year during the Term marketing and sales plans for the Product for all European
Territory countries for the following calendar year, commencing with the calendar
year in which Regulatory Approval is obtained in each respective European Territory
country. Such plans shall include the projected Annual Net Sales.

Sales Reports for Product. GTX shall provide to Orion, within forty-five
(45) days after the end of each calendar year, a written sales report for each of
the European Territory countries in which Product is launched.

	 	4.	 	This Amendment shall become effective on June 30, 2006.
	 
	 	5.	 	Except as specifically set forth and/or amended herein, all the
terms and conditions of the Agreement shall remain unchanged.

 

			
	[ * ]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.	 	 

2.

 

IN WITNESS WHEREOF,

the Parties, through their authorized representatives, have executed two (2)
identical copies of this Amendment.

	 	 	 	 	 	 	 	 	 	 	 
	 	 	Orion Corporation

ORION PHARMA	 	 	 	GTx Inc.
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	By: /s/ Timo Lappalainen
	 	 	 	By: /s/ Henry P. Doggrell
	 

	 	 

	 	 	 	 

	 

	 	Name: Timo Lappalainen
	 	 	 	Name: Henry P. Doggrell
	 

	 	Title: Senior Vice President
	 	 	 	Title: VP, General Counsel
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	By: /s/ Matti Vaheri	 	 	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 

	 	Name: Matti Vaheri	 	 	 	 	 	 
	 

	 	Title: Director, Global Alliance Management	 	 	 	 	 	 

 

			
	[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.	 	 

3.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]